B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: Clinical and molecular-histogenetic study of 17 cases from a single institution

Transplantation

Volumn 82, Issue 8, 2006, Pages 1013-1023

  Lucioni, Marco ^a   Capello, Daniela ^b   Riboni, Roberta ^a   Ippoliti, Giovanbattista ^c   Campana, Carlo ^d   Bandiera, Laura ^a   Arcaini, Luca ^a   Rossi, Davide ^b   Cerri, Michaela ^b   Dionigi, Paolo ^a   Lazzarino, Mario ^a   Magrini, Umberto ^a   Viganò, Mario ^a   Gaidano, Gianluca ^b   Paulli, Marco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Azienda Ospedaliera of Pavia   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Immunohistochemistry; Lymphoma; Molecular biology; Transplantation

Indexed keywords

BLEOMYCIN; CD20 ANTIBODY; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MITOXANTRONE; OKT 3; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; SYNDECAN 1; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOMYOPATHY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLONAL VARIATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; EPSTEIN BARR VIRUS; FEMALE; GENOTYPE; GERMINAL CENTER; GRAFT RECIPIENT; HEART TRANSPLANTATION; HISTOGENESIS; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MARKER GENE; PHENOTYPE; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS; SOMATIC HYPERMUTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 33750306387     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000232698.81689.50     Document Type: Article

References (56)

1. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101.
2. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552.
3. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82: 1978.
4. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200.
5. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.). Pathology and Genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:264-271.
6. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of postransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293.
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
8. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
9. Leblond V, Davi F, Charlotte F, et al. Post-transplant lymphoproliferative disorders not associated with Epstein-Barr Virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
10. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr Virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375.
11. Gao SZ, Chaparro SV, Pelroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22: 505.
12. Paya CV, Fung J, Nalesnik M, et al. Epstein-Barr Virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517.
13. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772.
14. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under Cyclosporine-steroid therapy. Lancet 1984; 584.
15. Müller-Hermelink HK, Greiner A. Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. Am J Pathol 1998; 153: 1341.
16. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520.
17. Stevenson FK, Sahota SS, Ottensmeier CH, et al. The occurrence and significance of V gene mutations in B cell derived human malignancy. Adv Cancer Res 2001; 83: 81.
18. Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280: 1750.
19. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B-cells. Blood 1995; 86: 45.
20. King BE, Chen C, Locker J, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod Pathol 2000; 13: 1219.
21. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells and activated cells. Blood 2000; 95: 2084.
22. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM-1/IRF4, bcl-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001; 97: 744.
23. Timms JM, Bell A, Flavell JR, et al. Target cells of Epstein-Barr-Virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003; 361: 217.
24. Bräuninger A, Spieker T, Mottok A, et al. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur J Immunol 2003; 33: 1593.
25. Capello D, Cerri M, Muti G, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003; 102: 3775.
26. Novoa-Takara L, Perkins SL, Qi D, et al. Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type. Solid organ vs hematopoetic stem cell transplantation. Am J Clin Pathol 2005; 123: 104.
27. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24: 671.
28. Lossos IS, Tibshirami N, Narasimhan B, Levy R. The interference of antigen selection on Ig genes. J Immunol 2000; 165: 5122.
29. Chang B, Casali P. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 1994; 15: 367.
30. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000; 95: 651.
31. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15: 647.
32. Reams BD, McAdams P, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation and response to treatment in lung transplant recipients. Chest 2003; 124: 1242.
33. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organ causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169.
34. Darenkov I, Marcarelli MA, Basadonna G, et al. Reduced incidence of Epstein-Barr Virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
35. Klein U, Fu Y, Stolovitzky GA, et al. Gene expression profiling of B-cell chronic lymphocytic leucemia reveals a homogeneous phenotype related to memory B-cells. J Exp Med 2001; 194: 1625.
36. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639.
37. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113.
38. Carbone A, Gaidano G, Gloghini A, et al. BCL-6 protein expression in AIDS-related Non-Hodgkin's lymphomas. Inverse relationship with Epstein-Barr Viru-encoded latent membrane protein-1 expression. Am J Pathol 1997; 150: 155.
39. Cattoretti G, Zhang J, Cleary AM, et al. Downregulation of BCL-6 gene expression by CD40 andd EBV latent membrane protein-1 (LMP-1) and its block in lymphoma carrying BCL-6 rearrangements. Blood 1997; 90: 175a.
40. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328.
41. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse lage B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503.
42. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937.
43. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78.
44. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275.
45. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464.
46. Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106: 1762.
47. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiac transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. N Engl J Med 1984; 310: 477.
48. Schubart DB, Rolink A, Kosco-Vilbois MH, et al. B-cell-specific coactivator OBF-1/OCA-B/Bob1 is required for immune response and germinal centre formation. Nature 1996; 383: 538.
49. Henderson A, Calame K. Transcriptional regulation during B cell development. Annu Rev Immunol 1998; 16: 163.
50. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000; 288: 1439.
51. Stein H, Marafioti T, Foss HD, et al. Down regulation of BOB.1/OBF.1 and Oct-2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97: 496.
52. Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 2001; 97: 3191.
53. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001; 159: 1807.
54. Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002; 99: 3060.
55. Loddenkemper C, Anagnostopoulos I, Hummel H, et al. Differential Eμ enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1 and immunoglobulin in reactive B-cell population, B-cell non Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004; 202: 60.
56. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma. High frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1 and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162: 243.